People: Pacira Pharmaceuticals Inc (PCRX.OQ)
PCRX.OQ on NASDAQ Stock Exchange Global Select Market
34.02USD
11:00am EDT
34.02USD
11:00am EDT
Price Change (% chg)
$-0.09 (-0.26%)
$-0.09 (-0.26%)
Prev Close
$34.11
$34.11
Open
$31.00
$31.00
Day's High
$34.92
$34.92
Day's Low
$30.75
$30.75
Volume
130,911
130,911
Avg. Vol
116,882
116,882
52-wk High
$35.86
$35.86
52-wk Low
$14.46
$14.46
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
Fred Middleton |
63 | Independent Chairman of the Board | |
David Stack |
61 | 2007 | President, Chief Executive Officer, Director |
James Scibetta |
48 | 2008 | Chief Financial Officer |
Lauren Riker |
34 | 2012 | Principal Accounting Officer, Executive Director - Accounting & Reporting |
Taunia Markvicka |
44 | 2011 | Vice President - Commercial |
John Pratt |
69 | 2012 | General Manager - San Diego Facility |
Gary Patou |
54 | 2009 | Chief Medical Officer |
Mark Kronenfeld |
2013 | Director | |
Laura Brege |
55 | 2011 | Independent Director |
Luke Evnin |
2006 | Independent Director | |
Paul Hastings |
2011 | Independent Director | |
John Longenecker |
65 | 2007 | Independent Director |
Gary Pace |
65 | 2008 | Independent Director |
Andreas Wicki |
54 | 2006 | Independent Director |
Biographies
| Name | Description |
|---|---|
Fred Middleton |
Mr. Fred A. Middleton is Independent Chairman of the Board of Pacira Pharmaceuticals Inc. Since 1987, he has been a general partner/managing director of Sanderling Ventures, a firm specializing in biomedical venture capital. From 1984 through 1986, he was the managing general partner of Morgan Stanley Ventures, an affiliate of Morgan Stanley & Co. Earlier in his career, Mr. Middleton was part of the of the founding management team at Genentech, Inc., a biotechnology company, serving there from 1978 through 1984 as vice president of finance and corporate development, and chief financial officer. During the last 30 years, he has participated in active management roles and as an investor and director in over 20 start-up biomedical companies. He currently serves as a director of Stereotaxis, Inc. (NASDAQ: STXS), a medical device company that markets magnetically guided robotic surgery systems in cardiology, and Endocyte, Inc. (NASDAQ: ECYT), a biopharmaceutical company developing targeted therapies for the treatment of cancer and inflammatory diseases. He served as a director of Cardionet, Inc. (NASDAQ: BEAT), a company that markets devices and services for wireless 24/7 real time monitoring of patients, from 2000 to May 2011. He also serves as a director of seven other privately-held biomedical companies, engaged in the development of therapeutic and diagnostic products in healthcare. Mr. Middleton received a B.S. degree in chemistry from the Massachusetts Institute of Technology and an M.B.A. from Harvard Business School. |
David Stack |
Mr. David M. Stack is President, Chief Executive Officer, Director of Pacira Pharmaceuticals Inc. Mr. Stack has been a managing director of MPM Capital since 2005 and a managing partner of Stack Pharmaceuticals, Inc. since 1998. From 2001 to 2004, he was president and chief executive officer of The Medicines Company (NASDAQ: MDCO). Previously, Mr. Stack was president and general manager at Innovex, Inc. He was vice president, business development/marketing at Immunomedics from 1993 until 1995. Prior to that, he was with Roche Laboratories in positions of increasing responsibility from 1981 until 1993, director, business development and planning, infectious disease, oncology, and virology. He currently serves as a member of the board of directors of PepTx, Inc., Medivo, Inc. and Amarin Corporation plc. He was a member of the boards of directors of Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) from 2006 to 2010 and BioClinica, Inc. (NASDAQ: BIOC) from 1999 to 2010. Mr. Stack holds a B.S. in pharmacy from Albany College of Pharmacy and a B.S. in Biology from Siena College. |
James Scibetta |
Mr. James S. Scibetta is Chief Financial Officer of Pacira Pharmaceuticals Inc. Prior to that, Mr. Scibetta was chief financial officer of Bioenvision, Inc. (NASDAQ: BIVN) from 2006 until its acquisition by Genzyme, Inc. in 2007. From 2001 to 2006, Mr. Scibetta was executive vice president and chief financial officer of Merrimack Pharmaceuticals, Inc., and he was a member of the board of directors of Merrimack from 1998 to 2004. Mr. Scibetta formerly served as a senior investment banker at Shattuck Hammond Partners, LLC and PaineWebber Inc., providing capital acquisition, merger and acquisition, and strategic advisory services to healthcare companies. He currently serves as chairman of the board and audit committee of Nephros, Inc. (NASDAQ: NEPH). Mr. Scibetta holds a B.S. in physics from Wake Forest University, and an M.B.A. in finance from the University of Michigan. He completed executive education studies in the Harvard Business School Leadership & Strategy in Pharmaceuticals and Biotechnology program. |
Lauren Riker |
Ms. Lauren Riker is Principal Accounting Officer, Executive Director - Accounting & Reporting of Pacira Pharmaceuticals, Inc. Ms. Riker served as Senior Director of Financial Reporting at Ikaria, Inc. ("Ikaria"), a private critical care biopharmaceutical company, from April 2008 to April 2011, where she was responsible for the oversight, monitoring and review of Ikaria's financial reporting, technical accounting and stock-based compensation program. From December 2004 to February 2008, Ms. Riker served as the Controller and later the Chief Accounting Officer of Bioenvision, Inc., ("Bioenvision") a publicly traded biotechnology company. Her responsibilities at Bioenvision included preparation of the financial statements and disclosures in accordance with United States generally accepted accounting principles and the reporting requirements of the SEC and implementation of internal controls and procedures in compliance with Sarbanes-Oxley. From 2000 to 2004, Ms. Riker worked at KPMG in the Information, Communication and Entertainment sector where she held positions of increasing responsibility, including Audit Manager. Ms. Riker holds a B.S. in accounting from Boston College and an M.B.A. from Columbia Business School. |
Taunia Markvicka |
Dr. Taunia Markvicka, Pharm. D. is Vice President - Commercial of Pacira Pharmaceuticals Inc. Dr. Markvicka is a partner at Stack Pharmaceuticals, Inc., a commercialization, marketing, and strategy firm, in addition to her role at Pacira. Her most recent pharmaceutical positions include serving as a franchise marketing director at The Medicines Company for cardiovascular and hematology acute care products. Previously, Dr. Markvicka was Marketing Director at Watson Pharmaceuticals, where she oversaw marketing, medical marketing and new product planning for urology and general products. She was also with Advantage Healthcare, a strategic marketing and new product planning firm, as a Vice President, for two years. She joined the pharmaceutical industry, initially taking a two year post-doctoral fellowship position with Sandoz (now Novartis). Dr. Markvicka holds a Doctor of Pharmacy degree from the University of Nebraska, an MBA from St. Joseph's University, and she maintains her license as a registered pharmacist. |
John Pratt |
Mr. John Pratt is General Manager - San Diego Facility of Pacira Pharmaceuticals, Inc. Prior to joining, Mr. Pratt was a general manager of Amylin Ohio LLC ("Amylin Ohio"), a subsidiary of Amylin Pharmaceuticals, from 2006 to 2011. In that role, Mr. Pratt managed a 305-person operations team while simultaneously directing Amylin Ohio's commercial operations and the design, construction and FDA acceptance of a 550,000 square foot, state-of-the-art manufacturing, inspection and packaging facility. Prior to his employment with Amylin Ohio, Mr. Pratt was employed by Novo Nordisk, where he held various senior management roles related to manufacturing operations and quality control. Mr. Pratt has a B.S. in Microbiology/Chemistry from the University of Montana and took post-graduate coursework at the University of Washington. |
Gary Patou |
Dr. Gary Patou, M.D., is Chief Medical Officer of Pacira Pharmaceuticals Inc. Dr. Patou has been a managing director of MPM Capital since 2005. He has served as chief medical officer of the following MPM Capital portfolio companies: Peplin, Ltd. (ASX: PLI), from June 2006 to April 2007 and from June 2008 to May 2009, Cerimon Pharmaceuticals, Inc., from June 2005 to June 2006, and Oscient Pharmaceuticals, Inc., from February 2004 to April 2005. From 2001 to 2004, he was president of Genesoft and from 1995 to 2000, Dr. Patou worked at SmithKline Beecham Pharmaceuticals, now a unit of GlaxoSmithKline (LSE: GSK), where he held positions of increasing responsibility including senior vice president and director, project and portfolio management. From 1991 to 1995, he held increasing senior, director level positions at Vernalis (LSE:VER), formerly British Biotechnology. He currently serves as a member of the board of directors of Xenon Pharmaceuticals, Inc. He served as a member of the board of directors of Oscient Pharmaceuticals Corporation (NASDAQ: OSCI) from 2005 to 2008. Dr. Patou has held a number of academic appointments at University College & Middlesex School of Medicine in London and holds an M.D. from University College, London. |
Mark Kronenfeld |
Dr. Mark A. Kronenfeld, M.D., has been appointed as Director of Pacira Pharmaceuticals, Inc., effective June 12, 2013. Dr. Kronenfeld has been the Vice Chairman of Anesthesiology at Maimonides Medical Center, since March 2009, and has served as Medical Director of Perioperative Services for Maimonides Medical Center since January 2011. Dr. Kronenfeld is a managing partner of Anesthesia Associates of Boro Park, a private medical practice, and a managing partner of Strategic Medical Management Partners. In 2001, Dr. Kronenfeld founded Ridgemark Capital Management (“Ridgemark”), a healthcare-focused hedge fund that invested in public and private healthcare and biomedical companies. He served as the Managing Partner and Portfolio Manager of Ridgemark from April 2001 to December 2008. Dr. Kronenfeld has founded and/or managed various consulting and investment companies focused on healthcare and medical technologies and has served on and chaired multiple leadership committees for various hospitals and medical centers. Previously, Dr. Kronenfeld taught and practiced adult and pediatric cardiac anesthesia at NYU and was Chief of Cardiac Anesthesiology at Hackensack University Medical Center and President of GMS Anesthesia Associates, a private medical practice. Dr. Kronenfeld received his M.D. degree and completed his residency in Anesthesiology at the University of California, San Diego School of Medicine, and completed a fellowship in Cardiothoracic Anesthesiology at New York University Medical Center. While an Assistant Professor and Attending Cardiac Anesthesiologist at NYU, Dr. Kronenfeld received and completed a Kellogg-sponsored Fellowship in Heath Care Management for Future Leaders in Health Care at NYU’s Graduate School of Management. |
Laura Brege |
Ms. Laura A. Brege is Independent Director of Pacira Pharmaceuticals Inc. Since September 2012, she has served as the president and chief executive officer of Nodality, Inc. Previously, Ms. Brege held the roles of chief operating officer and executive vice president and chief business officer for Onyx. Prior to joining Onyx in 2006, Ms. Brege was a general partner at Red Rock Capital Management, a venture capital firm, and senior vice president and chief financial officer at COR Therapeutics, Inc. Ms. Brege currently serves as a director of Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) and Delcath Systems, Inc. (NASDAQ: DCTH). She previously served as a member of the board of directors of Angiotech Pharmaceuticals Inc. from 2007 to 2011. Ms. Brege earned her undergraduate degree from Ohio University and has an M.B.A. from the University of Chicago. |
Luke Evnin |
Dr. Luke B. Evnin, Ph.D., is Independent Director of Pacira Pharmaceuticals Inc. Dr. Evnin has served as a general partner or managing director at MPM Capital since co-founding the firm in 1997. Prior to joining MPM, Dr. Evnin was at Accel Partners from 1990 to 1997, serving as general partner from 1994 to 1997. Dr. Evnin currently serves as director of EnteroMedics Inc. (NASDAQ: ETRM). He has previously been a member of the boards of EPIX Pharmaceuticals, Inc. (NASDAQ: EPIX), Metabasis Therapeutics, Inc. (NASDAQ: MBRX), Oscient Pharmaceuticals Corporation (NASDAQ: OSCI), Restore Medical, Inc., and Otix Global, Inc. (NASDAQ: OTIX), formerly known as Sonic Innovations, Inc. and Signal Pharmaceuticals, Inc. Mr. Evnin is currently or has been a director of several private healthcare companies in both the medical device and biopharmaceutical sectors. Dr. Evnin earned his Ph.D. in biochemistry from the University of California, San Francisco and his A.B. in molecular biology from Princeton University. |
Paul Hastings |
Mr. Paul J. Hastings is Independent Director of Pacira Pharmaceuticals Inc. Mr. Hastings has been the president and chief executive officer of OncoMed Pharmaceuticals, Inc. since January 2006. Prior to joining OncoMed, Mr. Hastings was president and chief executive officer of QLT, Inc. Before this role, Mr. Hastings served as president and chief executive officer of Axys Pharmaceuticals, Inc., which was acquired by Celera Corporation in 2001. Prior to Axys, Mr. Hastings was president of Chiron Biopharmaceuticals and also held a variety of management positions of increasing responsibility at Genzyme Corporation, including president of Genzyme Therapeutics Europe and president of Worldwide Therapeutics. Mr. Hastings was Chairman of the Board of Proteolix (sold to Onyx) and was a member of the board of directors of ViaCell Inc. (sold to Perkin Elmer). Mr. Hastings currently serves on the board of directors of Relypsa Inc., a clinical-stage biopharmaceutical company, and the Bay Area Biosciences Association (Bay Bio), and he is Chair of the Emerging Companies Section of the Biotechnology Industry Organization. He received a Bachelor of Science degree in pharmacy from the University of Rhode Island. |
John Longenecker |
Dr. John P. Longenecker, Ph.D., is Independent Director of Pacira Pharmaceuticals Inc. Dr. Longenecker has served as president and chief executive officer of HemaQuest Pharmaceuticals, Inc. since October 2010. From December 2009 to March 2010, Dr. Longenecker served as the president and chief executive officer of VitreoRetinal Technologies Inc. From February 2002 to January 2009, Dr. Longenecker was the president and chief executive officer and a member of the board of directors of Favrille, Inc. In 1992, Dr. Longenecker joined DepoTech as senior vice president of research, development and operations and then served as president and chief operating officer from February 1998 to March 1999. Under Dr. Longenecker's leadership, DepoTech took its lead product, DepoCyt(e), from early pre-clinical research and development through to commercial launch. Following SkyePharma PLC's acquisition of DepoTech in 1999, Dr. Longenecker served as president for the U.S. operations of SkyePharma, Inc. and as a member of the executive committee for SkyePharma PLC. From 1982 to 1992, Dr. Longenecker was at Scios Inc. (Cal Bio), a biotechnology company where he served as vice-president and director of development. Dr. Longenecker was also a director of a number of Cal Bio subsidiaries during this period including Meta Bio and Karo Bio. Dr. Longenecker holds a B.S. in chemistry from Purdue University and a Ph.D. in biochemistry from The Australian National University. He was a post-doctoral fellow at Stanford University from 1980 to 1982. |
Gary Pace |
Dr. Gary W. Pace, Ph.D., is Independent Director of Pacira Pharmaceuticals Inc. He is currently founder and chairman of the privately held Sova Pharmaceuticals Inc., founded in 2010. He is also founder, director and consultant to QRxPharma Ltd. (ASX:QRX) founded in 2001, a director of ResMed (NYSE:RMD) since 1994 and Transition Therapeutics Inc. (CDNX:TTH) since 2002. He previously served as a member of the board of directors at Celsion Corporation (NASDAQ: CLSN) from 2002 to 2010 and Peplin Inc. (ASX: PLI) from 2004 to 2009. He has more than 40 years of experience in the development and commercialization of advanced technologies, spanning biotechnology, pharmaceuticals, medical devices, and food industries. Dr. Pace was awarded a Centenary Medal by the Australian Government in 2003 "for service to Australian society in research and development" and was recognized as the 2011 Director of the Year (corporate governance) by the San Diego Directors Forum. Dr. Pace holds a B.Sc. with honors from the University of New South Wales and a Ph.D. from Massachusetts Institute of Technology. |
Andreas Wicki |
Dr. Andreas Wicki, Ph.D., is Independent Director of Pacira Pharmaceuticals Inc. Dr. Wicki is a life sciences entrepreneur and investor with over 20 years of experience in the pharmaceutical and biotechnology industries. Dr. Wicki has been chief executive officer of HBM Partners AG and HBM Healthcare Investments AG (formerly HBM BioVentures AG) since 2001. From 1998 to 2001, Dr. Wicki was the senior vice president of the European Analytical Operations at MDS Inc. From 1990 to 1998, he was co-owner and chief executive officer of ANAWA Laboratorien AG and Clinserve AG, two life sciences contract research companies. From 2007 to 2011, he served as a member of the board of directors of PharmaSwiss SA. Previously, Dr. Wicki held board positions on several privately-held companies and companies listed on international exchanges. Dr. Wicki holds an M.Sc. and Ph.D. in chemistry and biochemistry from the University of Bern, Switzerland. He currently serves on the board of directors of Buchler GmbH, HBM BioPharma India Ltd., HBM Healthcare Investments (Cayman) Ltd., HBM Partners Ltd., and HBM BioCapital Ltd. |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
Fred Middleton |
-- |
David Stack |
3,173,910 |
James Scibetta |
1,480,770 |
Lauren Riker |
-- |
Taunia Markvicka |
1,442,450 |
John Pratt |
-- |
Gary Patou |
436,660 |
Mark Kronenfeld |
-- |
Laura Brege |
-- |
Luke Evnin |
-- |
Paul Hastings |
-- |
John Longenecker |
-- |
Gary Pace |
-- |
Andreas Wicki |
-- |
As Of 30 Dec 2012
Options Compensation
| Name | Options | Value |
|---|---|---|
Fred Middleton |
0 | 0 |
David Stack |
0 | 0 |
James Scibetta |
0 | 0 |
Lauren Riker |
0 | 0 |
Taunia Markvicka |
0 | 0 |
John Pratt |
0 | 0 |
Gary Patou |
0 | 0 |
Mark Kronenfeld |
0 | 0 |
Laura Brege |
0 | 0 |
Luke Evnin |
0 | 0 |
Paul Hastings |
0 | 0 |
John Longenecker |
0 | 0 |
Gary Pace |
0 | 0 |
Andreas Wicki |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
WICKI ANDREAS |
19,938 | $35.28 |
WICKI ANDREAS |
56,020 | $34.98 |
WICKI ANDREAS |
4,042 | $34.80 |
WICKI ANDREAS |
21,518 | $33.20 |
WICKI ANDREAS |
350 | $33.20 |
WICKI ANDREAS |
48,132 | $33.28 |
MARKVICKA TAUNIA |
29,754 | $1.61 |
MARKVICKA TAUNIA |
29,754 | $32.00 |
WICKI ANDREAS |
80,000 | $31.48 |
WICKI ANDREAS |
44,021 | $30.80 |
WICKI ANDREAS |
50,000 | $30.67 |
WICKI ANDREAS |
60,597 | $29.85 |
PATOU GARY |
10,000 | $1.61 |
PATOU GARY |
10,000 | $30.00 |
WICKI ANDREAS |
3,851 | $29.85 |
PATOU GARY |
30,000 | $1.61 |
PATOU GARY |
30,000 | $29.25 |
STACK DAVID M |
15,000 | $28.73 |
LONGENECKER JOHN P |
804 | $1.61 |
SCIBETTA JAMES S |
10,000 | $1.61 |
STACK DAVID M |
15,000 | $1.61 |
LONGENECKER JOHN P |
2,000 | $28.09 |
SCIBETTA JAMES S |
10,000 | $28.05 |
LONGENECKER JOHN P |
1,196 | $1.61 |
MIDDLETON FRED A |
5,900 | $28.70 |

